<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797926</url>
  </required_header>
  <id_info>
    <org_study_id>116799</org_study_id>
    <nct_id>NCT01797926</nct_id>
  </id_info>
  <brief_title>Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in Healthy Adult Male and Female Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three-period, three sequence, reference replicated, cross-over study to determine&#xD;
      the bioequivalence of two amlodipine and losartan FDC tablet formulations FDC5/50 and&#xD;
      FDC5/100 (GSK2944406; 5 mg amlodipine and 50 mg and 100 mg losartan) to reference amlodipine&#xD;
      and losartan tablets co-administered in two groups enrolling 102 healthy adult male and&#xD;
      female subjects under fasting conditions.&#xD;
&#xD;
      A description of each treatment is provided below:&#xD;
&#xD;
      A (Reference) = 1 x 5 mg amlodipine tablet and 1 x 50 mg losartan tablet. B (FDC5/50) = 1 x 5&#xD;
      mg amlodipine and 50 mg losartan tablet C (Reference) = 1 x 5 mg amlodipine tablet and 1 x&#xD;
      100 mg losartan tablet D (FDC5/100) = 1 x 5 mg amlodipine and100 mg losartan tablet The&#xD;
      treatments will be administered in accordance with the randomisation schedule as.&#xD;
&#xD;
      Group 1: A → A → B or A → B → A or B → A → A Group 2: C → C → D or C → D → C or D → C → C All&#xD;
      subjects will attend a screening visit within 28 days of their first dosing period (Day 1).&#xD;
      The baseline assessments will be conducted the day before the first dosing.&#xD;
&#xD;
      In each treatment period, subjects will be admitted to the clinic in the evening before Day&#xD;
      1. All subjects will receive a single oral dose of amlodipine and losartan in the morning on&#xD;
      Day 1. All the subjects will remain in the clinical unit until completion of all assessments&#xD;
      at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample.&#xD;
      Subjects will return to the clinic for pharmacokinetic samples at 36, 48, 72 and 96 hours&#xD;
      post-dose.&#xD;
&#xD;
      The three treatment periods will be separated by a washout period of 10-17 days. Upon&#xD;
      completion of the last dosing period, or early withdrawal, subjects will return to the&#xD;
      clinical unit within 14-21 days for a follow up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2013</start_date>
  <completion_date type="Actual">July 25, 2013</completion_date>
  <primary_completion_date type="Actual">July 25, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for amlodipine and losartan in relevant treatments</measure>
    <time_frame>Up to 25 days at regular time points</time_frame>
    <description>Pharmacokinetic (PK) parameters for amlodipine and losartan will include the area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments AUC(0-t), area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time exposure over the dosing and interval area under the plasma concentration time curve (AUC (0- infinity)), and maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters tmax, Clast, percentage AUCex and t½ for amlodipine and losartan</measure>
    <time_frame>Up to 25 Days at regular time points</time_frame>
    <description>The PK parameters: time of occurrence of Cmax (tmax), last observed quantifiable concentration (Clast), percentage AUCex and terminal phase half-life (t½) will be determined from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic parameters for carboxylic acid (active losartan metabolite)</measure>
    <time_frame>Up to 25 Days at regular time points</time_frame>
    <description>The PK paramenters for carboxylic acid: AUC (0-t), AUC (0-infinity), Cmax, tmax, %AUCex, Clast and t½will be determined from the plasma concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of clinical laboratory test values to access safety and tolerability</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Clinical laboratory tests will include hematology, clinical chemistry and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by vital sign measurements</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Vital sign measurements will include pulse rate and blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AE)s</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Safety and tolerability parameters will include recording of AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1 (5 mg amlodipine and 50 mg losartan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (5 mg amlodipine and 100 mg losartan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Treatment: 5 mg amlodipine + 50 mg losartan</intervention_name>
    <description>Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose</description>
    <arm_group_label>Group 1 (5 mg amlodipine and 50 mg losartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Treatment:5 mg amlodipine + 100 mg losartan</intervention_name>
    <description>Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose</description>
    <arm_group_label>Group 2 (5 mg amlodipine and 100 mg losartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC 5/50 amlodipine/ losartan</intervention_name>
    <description>Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state</description>
    <arm_group_label>Group 1 (5 mg amlodipine and 50 mg losartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC 5/100 amlodipine /losartan</intervention_name>
    <description>Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state</description>
    <arm_group_label>Group 2 (5 mg amlodipine and 100 mg losartan)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &amp; Gender: Male or female between 18 and 65 years of age inclusive, at the time of&#xD;
             signing the informed consent.&#xD;
&#xD;
          -  Body weight &gt;= 50 kg and body mass index (BMI) within the range 18.5 to 24.9&#xD;
             kilogram/meter squared.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) alkaline phosphatase and bilirubin &lt;or=1.5x upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          -  Normal electrocardiogram (ECG) measurements. Average QT duration corrected for heart&#xD;
             rate by Fridericia's formula (QTcF) &lt;450 millisecond (msec) or QTcF &lt;480 msec in&#xD;
             subjects with Bundle Branch Block based on an average from three ECGs obtained over a&#xD;
             brief recording period.&#xD;
&#xD;
          -  Female subjects of non-child bearing potential. Females of child bearing potential are&#xD;
             eligible to enter if they are not pregnant and willing to use protocol-specified&#xD;
             methods of contraception to prevent pregnancy.&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             Evaluation.&#xD;
&#xD;
          -  Capable of giving written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a positive: drug/alcohol screen, Hepatitis, human immunodeficiency&#xD;
             virus(HIV) screen&#xD;
&#xD;
          -  Subject with systolic blood pressure less than 90 mmHg or diastolic less than 60 mm Hg&#xD;
             irrespective of associated symptoms at the time of admission&#xD;
&#xD;
          -  If there is a drop in 20 mmHg of systolic pressure (and a 10 mmHg drop in diastolic)&#xD;
             and a 20 beats per minute increase in heart rate between supine measurement and after&#xD;
             two minutes standing at the time of admission.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol at the time of admission.&#xD;
&#xD;
          -  Abuse of alcohol&#xD;
&#xD;
          -  Participated in a clinical trial and has received an investigational product within&#xD;
             the following time period prior to the first dosing day in the current study: 30 days,&#xD;
             5 half-lives or twice the duration of the biological effect of the investigational&#xD;
             product (whichever is longer)&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not&#xD;
             interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Donation of more than 500 milliliter (mL) blood within a 56 day period.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Subject having positive urinary cotinine levels indicative of use of tobacco or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma including childhood asthma.&#xD;
&#xD;
          -  Unable to refrain from consumption of red wine, Seville oranges, grapefruit or&#xD;
             grapefruit juice from 7 days prior to the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein,</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 21, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Hypertension</keyword>
  <keyword>losartan</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116799</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

